TIME
Contributing to TIME’s most widely read annual publications, we helped frame five important discussions: the ethics of human gene editing, what to expect from CRISPR technology over the next decade, the development of mRNA vaccines, the Telomere-to-Telomere Consortium’s breakthrough work, and the transformative impact of AI in bio.
TIME 100 2025
In the 2025 TIME100, Thermal collaborated on a feature honoring Demis Hassabis, CEO of Google DeepMind, recognized for his pioneering work in AI. The piece, penned by Nobel laureate and CRISPR pioneer Jennifer Doudna, delves into Hassabis’s development of AlphaFold – an AI tool revolutionizing biology by predicting protein structures – and his vision for AI’s role in addressing global challenges. This collaboration underscores our commitment to articulating the profound impact of AI on science and society. Read the full piece here.
TIME 100 2022
Ever since the draft of the human genome became available in 2001, there has been a nagging question about the genome’s “dark matter”—the parts of the map that were missed the first time through. To celebrate breakthrough work of the Telomere-to-Telomere Consortium of scientists, we assisted in spotlighting the full mapping of the human genomic landscape and what it could lead to. Read the full pieces here.
TIME 100 2021
In the 2021 TIME100, Thermal supported the feature honoring Dr. Katalin Karikó, whose decades-long dedication to mRNA research laid the groundwork for the Pfizer-BioNTech and Moderna COVID-19 vaccines. Authored by Nobel laureate Jennifer Doudna, the piece highlights Karikó’s perseverance in advancing mRNA technology, transforming a once-overlooked molecule into a cornerstone of modern medicine. This collaboration underscores our commitment to amplifying the stories of scientists whose innovations have a profound impact on global health. Read the full piece here.
TIME 100 2019
How can we educate the public on a shocking abuse of the CRISPR gene editing and support the reputation of a technology that can, if used safely and appropriately, help improve the lives of millions?
We assisted in the development of a timely piece discussing the scientist that abused CRISPR-Cas9 gene editing technology in one of the most shocking misapplications of any scientific tool in our history.
The resulting TIME 100 opinion piece framed the reckless experimentation on twin girls in China that shattered scientific, medical and ethical norms but also focused on how we can safely apply genome editing to cure genetic diseases, fight cancer, accelerate drug development, create transplant organs and develop more nutritious crops.
TIME Health 2019
When we helped publish “The Gene-Editing Revolution Is Already Here” in TIME in 2019, CRISPR was still largely seen as a promise on the horizon. The goal was to shift the conversation – from speculative to actionable – by outlining the investments, partnerships, and policy frameworks needed to responsibly scale the technology.
Now, as CRISPR therapies begin reaching patients, that vision is becoming real. The op-ed laid out a future in which we treat genetic disease like an outpatient condition—and today, that future is closer than ever.
